ExodusPoint Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

ExodusPoint Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-128,955	Closed	-$3.38M	–	2227
2022 Q4	$3.38M	Sell	128,955 -41,701	-24%	-$924K	0.05%	463
2022 Q3	$3.35M	Buy	170,656 +10,178	+6%	+$204K	0.04%	550
2022 Q2	$2.81M	Buy	+160,478	New	+$2.52M	0.03%	642
2021 Q2	–	Sell	-13,852	Closed	-$215K	–	2955
2021 Q1	$215K	Buy	+13,852	New	+$226K	﹤0.01%	1843

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ExodusPoint Capital Management's KDNY Position: Q1 2023 in Review

ExodusPoint Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 128,955 shares — an estimated $3.38M sold.

ExodusPoint Capital Management first reported a position in KDNY in Q1 2021 and held it in 4 quarters. The position peaked at $3.38M in Q4 2022. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

ExodusPoint Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 128,955 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $3.38M.
ExodusPoint Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
ExodusPoint Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $3.38M in Q4 2022.
157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.